[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100579753":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":11,"centralContacts":29,"locations":35,"responsibleParty":55,"collaborators":57,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":11,"eligibilityCriteria":66,"healthyVolunteers":67,"sex":68,"minAge":69,"maxAge":70,"enrollmentInfo":71,"targetDuration":11,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":11,"overallStatus":38,"whyStopped":11,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"Seismic Therapeutic AU Pty Ltd","INDUSTRY",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"S-1117 Part 1: Single ascending dose (SAD) cohorts","EXPERIMENTAL",null,[13,14],"Drug: S-1117","Other: Placebo",{"label":16,"type":10,"description":11,"interventionNames":17},"S-1117 Part 2: Multiple ascending dose (MAD) cohorts",[13,14],[19,24],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":11},"DRUG","S-1117","S-1117 via subcutaneous or intravenous administration.",[9,16],{"type":25,"name":26,"description":27,"armGroupLabels":28,"otherNames":11},"OTHER","Placebo","Placebo via subcutaneous or intravenous administration.",[9,16],[30],{"name":31,"role":32,"phone":33,"phoneExt":11,"email":34},"Seismic Contact","CONTACT","1800 244 475","clinical@seismictx.com",[36],{"facility":37,"status":38,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"CMAX Clinical Research","RECRUITING","Adelaide","South Australia","5000","Australia","AU",{"type":45,"coordinates":46},"Point",[47,48],138.59863,-34.92866,{"lat":48,"lon":47},[51],{"name":52,"role":32,"phone":53,"phoneExt":11,"email":54},"CMAX Contact","1800 150 433","cmax@cmax.com.au",{"type":56,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR",[58],{"name":59,"class":6},"Avance Clinical Pty Ltd.","100579753","phase-1-a-phase-1-study-of-s-1117-100579753",false,"NCT06828393","A Phase 1 Study of S-1117","A Phase 1, Randomized, Placebo-Controlled, Double-Blind, Single and Multiple Ascending Dose Trial of S-1117 in Healthy Volunteers","Major Inclusion Criteria:\n\n1. Is available for the entire duration of the study and follow up.\n2. Is willing and able to comply with all study assessments and adhere to the protocol schedule and restrictions.\n3. Voluntarily consents to participation in the trial as documented by signing the study informed consent form (ICF).\n4. Has a body mass index (BMI) within 18 to 32 kg\u002Fm2, inclusive, and weighs ≥45 kg.\n5. Is in good physical and mental health in the opinion of the Investigator or delegate.\n\nMajor Exclusion Criteria:\n\n1. Has a history of severe allergic or anaphylactic reaction as determined by the Investigator or delegate.\n2. Is pregnant, nursing, or is planning to become pregnant or breastfeed during the trial.\n3. Has a known immunodeficiency disorder.\n4. Has a history of malignancy other than non-melanoma skin cancer.\n5. Has a history of human immunodeficiency virus (HIV) or positive serology for HIV at Screening.\n6. Has positive laboratory evidence for active hepatitis at screening.\n7. Has received a live vaccine within 2 months of Screening.\n8. Has any other condition or prior therapy that, in the opinion of the Investigator or delegate, may potentially compromise the safety or compliance of the participant, or may preclude the participant from successfully completing the study.\n\nOther inclusion\u002Fexclusion eligibility criteria apply.",true,"ALL","18 Years","65 Years",{"count":72,"type":73},96,"ESTIMATED","INTERVENTIONAL",[76],"PHASE1","This is the first-in-human study of S-1117 designed to provide safety, tolerability, pharmacokinetic, and pharmacodynamic data in healthy volunteers.",[79],"Healthy Volunteer","2025-03-09",{"date":82,"type":83},"2025-03-12","ACTUAL",{"date":85,"type":73},"2025-03",{"date":87,"type":73},"2026-03",{"name":5,"class":6},1]